dupilumab对伴有严重特应性皮炎的斑秃的双重影响:一个病例系列和文献综述

IF 1.1 Q4 ALLERGY

Journal of Cutaneous Immunology and Allergy Pub Date : 2022-11-29 DOI:10.1002/cia2.12289

Masahiro Fukuyama MD, PhD, Misaki Kinoshita-Ise MD, PhD, Yoshiko Mizukawa MD, PhD, Manabu Ohyama MD, PhD

{"title":"dupilumab对伴有严重特应性皮炎的斑秃的双重影响:一个病例系列和文献综述","authors":"Masahiro Fukuyama MD, PhD, Misaki Kinoshita-Ise MD, PhD, Yoshiko Mizukawa MD, PhD, Manabu Ohyama MD, PhD","doi":"10.1002/cia2.12289","DOIUrl":null,"url":null,"abstract":"Alopecia areata (AA) often coexists with atopic dermatitis (AD). Recently, several reports suggested that dupilumab, an interleukin 4 receptor α‐antagonist, administration could be a promising medication not only for severe AD but also for AA concomitant with AD (AD‐AA). At the same time, dupilumab has also been reported to exacerbate AA in AD‐AA cases. Thus, the efficacy of dupilumab on AA in AD‐AA cases remains controversial.","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12289","citationCount":"4","resultStr":"{\"title\":\"Two-sided influence of dupilumab on alopecia areata co-existing with severe atopic dermatitis: A case series and literature review\",\"authors\":\"Masahiro Fukuyama MD, PhD, Misaki Kinoshita-Ise MD, PhD, Yoshiko Mizukawa MD, PhD, Manabu Ohyama MD, PhD\",\"doi\":\"10.1002/cia2.12289\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Alopecia areata (AA) often coexists with atopic dermatitis (AD). Recently, several reports suggested that dupilumab, an interleukin 4 receptor α‐antagonist, administration could be a promising medication not only for severe AD but also for AA concomitant with AD (AD‐AA). At the same time, dupilumab has also been reported to exacerbate AA in AD‐AA cases. Thus, the efficacy of dupilumab on AA in AD‐AA cases remains controversial.\",\"PeriodicalId\":15543,\"journal\":{\"name\":\"Journal of Cutaneous Immunology and Allergy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2022-11-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12289\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cutaneous Immunology and Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12289\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12289","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 4

摘要

斑秃（AA）常与特应性皮炎（AD）共存。最近，一些报道表明，白细胞介素4受体α拮抗剂dupilumab的给药不仅对严重AD，而且对伴有AD的AA（AD‐AA）都是一种有前景的药物。同时，据报道，在AD‐AA病例中，dupilumab也会加重AA。因此，在AD‐AA病例中，杜匹单抗对AA的疗效仍然存在争议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Two-sided influence of dupilumab on alopecia areata co-existing with severe atopic dermatitis: A case series and literature review

查看原文本刊更多论文

Two-sided influence of dupilumab on alopecia areata co-existing with severe atopic dermatitis: A case series and literature review

Alopecia areata (AA) often coexists with atopic dermatitis (AD). Recently, several reports suggested that dupilumab, an interleukin 4 receptor α‐antagonist, administration could be a promising medication not only for severe AD but also for AA concomitant with AD (AD‐AA). At the same time, dupilumab has also been reported to exacerbate AA in AD‐AA cases. Thus, the efficacy of dupilumab on AA in AD‐AA cases remains controversial.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cutaneous Immunology and Allergy Medicine-Dermatology

CiteScore

0.60

自引率

10.00%

发文量

审稿时长

12 weeks